Funding for this research was provided by:
Wellcome Trust (202778/B/16/Z)
Cancer Research UK (A22909)
Text and Data Mining valid from 2020-03-27
Received: 7 August 2019
Accepted: 18 February 2020
First Online: 27 March 2020
: G.S. is employee of AstraZeneca UK and also shareholder. A.A. is a co-founder of Tango Therapeutics, Azkarra Therapeutics, Ovibio Corporation; a consultant for SPARC, Bluestar, TopoRx, ProLynx; a member of the SAB of Genentech and GLAdiator; receives grant/research support from SPARC and AstraZeneca; A.A. holds patents on the use of PARP inhibitors held jointly with AstraZeneca which he has benefitted financially (and may do so in the future) through the ICR Rewards to Inventors Scheme.